Cargando…

Withania somnifera modulates cancer cachexia associated inflammatory cytokines and cell death in leukaemic THP-1 cells and peripheral blood mononuclear cells (PBMC’s)

BACKGROUND: Cancer and inflammation are associated with cachexia. Withania somnifera (W. somnifera) possesses antioxidant and anti-inflammatory potential. We investigated the potential of an aqueous extract of the root of W. somnifera (W(RE)) to modulate cytokines, antioxidants and apoptosis in leuk...

Descripción completa

Detalles Bibliográficos
Autores principales: Naidoo, Dhaneshree Bestinee, Chuturgoon, Anil Amichund, Phulukdaree, Alisa, Guruprasad, Kanive Parashiva, Satyamoorthy, Kapaettu, Sewram, Vikash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891897/
https://www.ncbi.nlm.nih.gov/pubmed/29631586
http://dx.doi.org/10.1186/s12906-018-2192-y
Descripción
Sumario:BACKGROUND: Cancer and inflammation are associated with cachexia. Withania somnifera (W. somnifera) possesses antioxidant and anti-inflammatory potential. We investigated the potential of an aqueous extract of the root of W. somnifera (W(RE)) to modulate cytokines, antioxidants and apoptosis in leukaemic THP-1 cells and peripheral blood mononuclear cells (PBMC’s). METHODS: Cytotoxcity of W(RE) was determined at 24 and 72 h (h). Oxidant scavenging activity of W(RE) was evaluated (2, 2-diphenyl-1 picrylhydrazyl assay). Glutathione (GSH) levels, caspase (− 8, − 9, − 3/7) activities and adenosine triphosphate (ATP) levels (Luminometry) were thereafter assayed. Tumour necrosis factor-α (TNF-α), interleukin (IL)-6, IL-1β and IL-10 levels were also assessed using enzyme-linked immunosorbant assay. RESULTS: At 24 h, W(RE) (0.2–0.4 mg/ml) decreased PBMC viability between 20 and 25%, whereas it increased THP-1 viability between 15 and 23% (p < 0.001). At 72 h, W(RE) increased PBMC viability by 27–39% (0.05, 0.4 mg/ml W(RE)) whereas decreased THP-1 viability between 9 and 16% (0.05–0.4 mg/ml W(RE)) (p < 0.001). Oxidant scavenging activity was increased by W(RE) (0.05–0.4 mg/ml, p < 0.0001). PBMC TNF-α and IL-10 levels were decreased by 0.2–0.4 mg/ml W(RE,) whereas IL-1β levels were increased by 0.05–0.4 mg/ml W(RE) (p < 0.0001). In THP-1 cells, W(RE) (0.05–0.4 mg/ml) decreased TNF-α, IL-1β and IL-6 levels (p < 0.0001). At 24 h, GSH levels were decreased in PBMC’s, whilst increased in THP-1 cells by 0.2–0.4 mg/ml W(RE) (p < 0.0001). At 72 h, W(RE) (0.1–0.4 mg/ml) decreased GSH levels in both cell lines (p < 0.0001). At 24 h, W(RE) (0.2–0.4 mg/ml) increased PBMC caspase (-8, -3/7) activities whereas W(RE) (0.05, 0.1, 0.4 mg/ml) increased THP-1 caspase (-9, -3/7) activities (p < 0.0001). At 72 h, PBMC caspase (-8, -9, -3/7) activities were increased at 0.05–0.1 mg/ml W(RE) (p < 0.0001). In THP-1 cells, caspase (-8, -9, -3/7) activities and ATP levels were increased by 0.1–0.2 mg/ml W(RE,) whereas decreased by 0.05 and 0.4 mg/ml W(RE) (72 h, p < 0.0001). CONCLUSION: In PBMC’s and THP-1 cells, W(RE) proved to effectively modulate antioxidant activity, inflammatory cytokines and cell death. In THP-1 cells, W(RE) decreased pro-inflammatory cytokine levels, which may alleviate cancer cachexia and excessive leukaemic cell growth. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12906-018-2192-y) contains supplementary material, which is available to authorized users.